The Great Divide? Implications of the SPC Waiver

[{“id”:”crh48lwb93wac”,”elType”:”container”,”settings”:{“flex_direction”:”column”},”elements”:[{“id”:”5820cba”,”elType”:”container”,”settings”:[],”elements”:[{“id”:”_crh48lwb93wjo”,”elType”:”widget”,”settings”:{“editor”:”Read Ayesha Raghib Q&A article in Pharma Technology Europe here about the SPC manufacturing waiver.”,”drop_cap”:”no”,”typography_typography”:”custom”,”typography_letter_spacing”:{“unit”:”px”,”size”:”0″},”typography_font_size”:{“unit”:”px”,”size”:”18″},”size”:”18″,”typography_font_weight”:”400″,”typography_line_height”:{“unit”:”px”,”size”:”28″},”title_color”:”#4b2771″,”text_color”:”#4b2771″,”color”:”#4b2771″,”align”:”start”},”widgetType”:”text-editor”}],”isInner”:false}],”isInner”:false}]